文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性癌症中的GRPR表达:GRPR放射性配体治疗潜在应用综述

GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy.
PubMed 文献 · Semin Nucl Med · 2025-08-11

本综述总结胃泌素释放肽受体(GRPR)在多种恶性肿瘤中的过表达及其作为放射性核素治疗靶点的潜力,涵盖前列腺癌、乳腺癌、肺癌、黑色素瘤、宫颈癌、神经母细胞瘤、头颈癌和结肠癌。文章讨论GRPR表达异质性与转移分布对患者选择和治疗优化的挑战,并介绍AMTG等新型化合物及铽-161、铅-212、铜-67、钴-58m、砷-77等创新核素。临床前与早期临床研究显示在 prostate 和宫颈癌中肿瘤靶向与疗效令人鼓舞、毒性可控,但需进一步研究GRPR表达异质性、转移分布与安全性以优化患者分层。

要点

  • GRPR在多种肿瘤中过表达,宫颈癌和神经母细胞瘤中表达较高,是放射性核素治疗的潜力靶点。
  • AMTG等新型化合物通过改善蛋白水解抗性和白蛋白结合域延长循环半衰期,增强肿瘤摄取。
  • 铽-161、铅-212、铜-67、钴-58m和砷-77等核素具Auger电子发射和α粒子治疗等有利衰变特性。

核心结论

  • GRPR靶向放射性核素治疗(GRPR-TRT)是一种多用途且强效的方法,有潜力将靶向放射性核素治疗扩展到更广泛的恶性肿瘤并改善治疗选择有限的晚期癌症的结局。

研究设计与样本

  • 本综述总结了GRPR在转移性癌症中的表达及GRPR放射性配体治疗的潜在应用。

主要发现

  • GRPR在包括前列腺、乳腺、肺、黑色素瘤、宫颈、神经母细胞瘤、头颈和结肠癌等多种肿瘤类型中过表达。
  • 宫颈癌和神经母细胞瘤中观察到GRPR高表达,但肿瘤异质性和转移特征仍是患者选择和治疗优化的挑战。
  • AMTG等新型化合物具有改善的蛋白水解抗性和白蛋白结合域以延长循环半衰期。
  • 铽-161、铅-212、铜-67、钴-58m和砷-77等创新核素通过有利的衰变特性(包括Auger电子发射和α粒子治疗)提供超越当前镥-177标准的治疗潜力。
  • 临床前和早期临床研究显示,尤其在前列腺癌和宫颈癌中,肿瘤靶向和治疗疗效令人鼓舞且毒性特征可控。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究GRPR表达异质性、转移分布和安全性,以完善患者分层并最大化临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastrin-Releasing Peptide Receptor (GRPR) represents a promising molecular target for radionuclide therapy (TRT) across a variety of malignancies due to its overexpression in several tumor types, including prostate, breast, lung, melanoma, cervix, neuroblastoma, head and neck, and colon cancers. While expression patterns vary-with high GRPR expression notably observed in cervix and neuroblastoma cancers-tumor heterogeneity and metastatic profiles remain challenges for patient selection and therapy optimization. Recent advances in GRPR-targeted radiopharmaceutical development have focused on overcoming peptide instability and enhancing tumor uptake, exemplified by novel compounds such as AMTG with improved proteolytic resistance and albumin binding domains to extend circulatory half-life. Furthermore, innovative radionuclides like terbium-161, lead-212, copper-67, cobalt-58 m, and arsenic-77 offer enhanced therapeutic potential beyond the current standard of lutetium-177 through favorable decay characteristics including Auger electron emission and alpha-particle therapy. Preclinical and early clinical studies demonstrate encouraging tumor targeting and therapeutic efficacy with manageable toxicity profiles, particularly in prostate and cervix cancers. However, further investigation into GRPR expression heterogeneity, metastatic distribution, and safety is necessary to refine patient stratification and maximize clinical benefit. This evolving landscape positions GRPR-TRT as a versatile and potent approach, with the potential to expand targeted radionuclide therapy to a broader range of malignancies and improve outcomes in advanced cancers with limited treatment options.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Callaud A, Duan H, Hindié E, et al. GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy. Semin Nucl Med. 2025. PMID: 40796452. doi:10.1053/j.semnuclmed.2025.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。